Is Aspirin Intake Associated With Risk of Bladder Cancer or Its Prognosis?
Posted: Thursday, September 9, 2021
Aspirin has been found to demonstrate antitumor activity; however, a retrospective case-control study and literature meta-analytic assessment published in Frontiers in Oncology did not show a strong relevant association between aspirin intake and the incidence of bladder cancer or its prognosis. Dr. Bo Fan, of the Second Affiliated Hospital of Dalian Medical University, China, and colleagues explained that further research is needed to confirm these findings.
A total of 1,121 patients with bladder cancer and 2,242 controls from Northeast China were included in the case-control study. Regular use of aspirin did not seem to be associated with a reduced incidence of bladder cancer (P = .175). Aspirin intake did not appear to reduce the risk of bladder cancer in females (P = .063); however, males who regularly took aspirin had a lower incidence of bladder cancer (P = .021). There seemed to be a significant reduction in the risk of bladder cancer in current smokers who took aspirin (P = .002). Compared with aspirin nonusers, aspirin users did not seem to experience a markedly longer duration of overall or recurrence-free survival. The analysis stratified by sex did not demonstrate a correlation between aspirin intake and recurrence of bladder cancer or survival outcomes for either male or female patients; however, in those younger than age 68, aspirin intake seemed to prolong the duration of overall survival (P = .019).
Based on the combined results from 19 articles and more than 39,524 cases, aspirin intake did not seem to be associated with the occurrence of bladder cancer (P = .671); this finding also appeared to hold true across the subgroups stratified by history of aspirin intake, mean duration of aspirin intake, sex, smoking exposure, research region, and study type. The combined results from 11 articles and 8,825 cases demonstrated that aspirin intake did not seem to have a significant influence on survival, recurrence, disease progression, or metastasis.
Disclosure: The study authors reported no conflicts of interest.